Pfizer yesterday announced positive results from their phase III clinical trial comparing prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly, with on-demand treatment for moderately severe to severe hemophilia B. Top-line results showed that the clinical trial met its primary endpoint, with a statistically noteworthy reduction in the annualised bleeding rate in
David Willetts, the UK’s Science Minister, yesterday announced an investment of £52 million for the UK’s science sectors to improve skills and vocational training. The announcement was made at the official launch of the Science and Industrial Partnership (SIP), which is being led by GlaxoSmithKline (GSK). The announcement is expected to create over ‘7,800 education
The European Commission have given marketing authorisation to use Nexavar, oral multi-kinase inhibitor, to treat the most common form of thyroid cancer, expanding the approved uses for the drug. Nexavar, which has previously received regulatory approval for advanced kidney and liver cancers, has now been approved for the treatment of metastatic differentiated thyroid carcinoma (DTC)
US regulatory body, the Food and Drug Administration (FDA), have granted breakthrough therapy status to Bristol-Myers Squibb and AbbVie’s elotuzumab to treat multiple myeloma (MM). The designation has been granted by the FDA for elotuzumab’s use with lenalidomide and dexamethasone in patients who have previously received one or more therapies to treat multiple myeloma. Elotuzumab
Results from three late-stage clinical trials have demonstrated that Eli Lilly’s diabetes drug, Peglispro, is more effective at reducing blood sugar in patients with type II diabetes than Sanofi’s Lantus. Yesterday, Eli Lilly confirmed that they are expecting to file for regulatory approval by the first quarter of 2015, after the Phase III clinical studies
Novartis have released data from a phase III clinical trial suggesting that their somatostatin analogue, Signifor, could be effective for the growth hormone disorder, acromegaly. The recent clinical trial assessed a once-monthly intramuscular formulation, named Signifor LAR, in patients with acromegaly where standard therapies had been ineffective. Signifor has already been approved by regulators in
Earlier this year, Clinical Professionals launched their 2014 pharmaceutical salary survey, as a service to the pharma industry. We are pleased to announce that we have had a fantastic response to the survey so far, and have now sent out over 1,000 complimentary copies to clients and candidates in the first quarter. As a result
find but how will it be implemented?” src=”http://i58.tinypic.com/11kyuxj.jpg” width=”214″ height=”136″ />Last week, Boris Johnson announced the launch of MedCity, a partnership of the UK’s top scientists, life science companies, and investors across London, Cambridge and Oxford. MedCity was set up by the Mayor and King’s Health Partners, Imperial College Academic Health Science Centre and UCL
Cytos Biotechnology yesterday announced that their Phase IIb clinical study of CYT003 failed to meet its primary or secondary endpoints. The clinical trial tested patients with moderate to severe allergic asthma, and showed that the immune modulator did not achieve a statistically significant reduction of the Asthma Control Questionnaire (ACQ) score at week 12 in
click Xalkori” src=”http://i61.tinypic.com/kng1x.jpg” width=”204″ height=”126″ />Pfizer have announced positive late-stage clinical data from a phase III trial of Xalkori, in comparison to chemotherapy. Pfizer revealed that the clinical study met the primary objective of significantly prolonging progression-free survival in previously-untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-squamous non-small cell lung cancer (NSCLC), when compared
